Bristol Myers gets priority review for first-line Reblozyl; Two startups clinch new cash

Bristol Myers Squibb is on the cusp of a new FDA decision. And it could come in the first-line setting.

The NJ-based Big Pharma said Monday that US regulators accepted a supplemental NDA for Reblozyl, also known as luspatercept, to treat anemia in adults with “very low- to intermediate-risk” myelodysplastic...

Click to view original post